<p>摩根士丹利的投資分析師在週五發佈的一份報告中將阿卡迪亞製藥（NASDAQ:ACAD）的目標股價從 30.00 美元下調至 28.00 美元。該公司目前對這家生物製藥公司的股票給予&#34;超配&#34;評級。摩根士丹利的價格目標表明，相較於公司當前股價，有 57.84% 的潛在上漲空間。</p>
<p>獲取 <strong>阿卡迪亞製藥</strong> 的警報：</p>
<ul>
<li>阿卡迪亞製藥：中型生物科技公司正在發生重大變化</li>
</ul>
<p>ACAD 已成為其他幾份研究報告的主題。Oppenheimer 重申了&#34;市場表現&#34;評級，並在 5 月 6 日的報告中對阿卡迪亞製藥的股票設定了 19.00 美元的價格目標。加拿大皇家銀行重申了&#34;表現優異&#34;評級，並在 6 月 25 日的報告中將阿卡迪亞製藥的股票目標價設定為 29.00 美元。Robert W. Baird 將阿卡迪亞製藥的目標股價從 31.00 美元下調至 28.00 美元，併為該公司設定了&#34;表現優異&#34;評級。Mizuho 將阿卡迪亞製藥的目標股價從 25.00 美元下調至 21.00 美元，併為該公司設定了&#34;中性&#34;評級。最後，摩根大通將阿卡迪亞製藥的目標股價從 29.00 美元下調至 25.00 美元，併為該公司設定了&#34;超配&#34;評級。四位股票研究分析師對該股票給予持有評級，十三位給予買入評級，一位給予強烈買入評級。根據 MarketBeat.com 的數據，該股目前的共識評級為&#34;中等買入&#34;，平均目標股價為 28.59 美元。</p>
<p><strong>查看我們對阿卡迪亞的最新研究報告</strong></p>
<h2>阿卡迪亞製藥股價表現</h2>
<p>週五午盤交易中，ACAD 股價上漲 0.09 美元，達到 17.74 美元。該股交易量為 700,451 股，相比平均交易量 1,724,612 股有所下降。該公司的市值為 29.3 億美元，市盈率為-1,772.23，β係數為 0.38。該公司的 50 天簡單移動平均線為 15.58 美元，200 天簡單移動平均線為 20.60 美元。阿卡迪亞製藥的 52 周最低價為 14.55 美元，最高價為 33.99 美元。</p>
<p>阿卡迪亞製藥（NASDAQ:ACAD）於 5 月 8 日公佈了其季度財報。這家生物製藥公司報告稱，該季度每股收益為 0.10 美元，超過了每股 0.04 美元的共識預期 0.06 美元。該季度公司營收為 2.0583 億美元，低於分析師預期的 2.0831 億美元。阿卡迪亞製藥的淨資產回報率為-0.41%，淨利潤率為-0.21%。與去年同期相比，阿卡迪亞製藥的營收增長了 73.8%。去年同期，該公司每股收益為（0.27）美元。分析師預計，阿卡迪亞製藥本財年的每股收益將為 0.58 美元。</p>
<h2>內部交易活動</h2>
<p>另外，首席執行官 Stephen Davis 於 5 月 2 日星期四以每股 16.94 美元的均價出售了 11,427 股阿卡迪亞製藥股票。交易完成後，首席執行官在公司中直接持有 155,231 股股票，價值 2,629,613.14 美元。該交易已在提交給證券交易委員會的文件中披露，可通過此鏈接訪問。此外，首席財務官 Mark C. Schneyer 於 5 月 2 日星期四以每股 16.94 美元的均價出售了 3,503 股公司股票。交易總價值為 59,340.82 美元。交易完成後，首席財務官現在持有公司股票 32,053 股，價值 542,977.82 美元。該交易已在提交給證券交易委員會的法律文件中披露，可通過此鏈接訪問。此外，首席執行官 Stephen Davis 於 5 月 2 日星期四以每股 16.94 美元的均價出售了 11,427 股公司股票。交易總價值為 193,573.38 美元。交易完成後，首席執行官在公司中直接持有 155,231 股股票，價值約 2,629,613.14 美元。有關此次交易的披露可在此處找到。過去 90 天，內部人士共出售 20,708 股公司股票，價值 348,697 美元。公司內部人士持有公司股份的比例為 28.30%。</p>
<h2>阿卡迪亞製藥的機構交易</h2>
<p>一些對沖基金和其他機構投資者最近調整了他們對該股票的持股。Empire Life Investments Inc. 在第四季度增加了對 ACADIA Pharmaceuticals 股份的持股比例，增長了 0.3%。Empire Life Investments Inc. 現在擁有 174,815 股這家生物製藥公司的股票，價值$5,473,000，上季度購買了額外的 467 股。Handelsbanken Fonder AB 在第四季度增加了對 ACADIA Pharmaceuticals 股份的持股比例，增長了 2.3%。Handelsbanken Fonder AB 現在擁有 31,633 股這家生物製藥公司的股票，價值$990,000，上季度購買了額外的 700 股。瑞士國家銀行在第一季度增加了對 ACADIA Pharmaceuticals 股份的持股比例，增長了 0.4%。瑞士國家銀行現在擁有 210,604 股這家生物製藥公司的股票，價值$3,894,000，上季度購買了額外的 800 股。Franklin Resources Inc. 在第四季度增加了對 ACADIA Pharmaceuticals 股份的持股比例，增長了 1.6%。Franklin Resources Inc. 現在擁有 50,405 股這家生物製藥公司的股票，價值$1,578,000，上季度購買了額外的 803 股。最後，Covestor Ltd 在第一季度增加了對 ACADIA Pharmaceuticals 股份的持股比例，增長了 70.5%。Covestor Ltd 現在擁有 2,032 股這家生物製藥公司的股票，價值$38,000，上季度購買了額外的 840 股。機構投資者持有該公司股份的 96.71%。</p>
<h2>關於 ACADIA Pharmaceuticals（獲取免費報告）</h2>
<p>ACADIA Pharmaceuticals Inc. 是一家生物製藥公司，專注於開發和商業化解決美國中樞神經系統（CNS）疾病和罕見疾病未滿足醫療需求的創新藥物。該公司提供 NUPLAZID（pimavanserin）用於治療帕金森病精神病的幻覺和妄想；以及 DAYBUE，一種胰島素樣生長因子 1 氨基末端三肽的新型合成類似物，用於治療雷特綜合徵。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們比 ACADIA Pharmaceuticals 更喜歡的股票</li>
<li>現在購買的 3 家最佳金融科技股</li>
<li>前三家飲料股：夏季收益揭示關鍵趨勢</li>
<li>股息王子寶潔在盈利下滑後值得購買</li>
<li>這家金融股的盈利信號表明購買機會</li>
<li>什麼是熱門股票？熱門股票解析</li>
<li>社交平台股價創新高：未來還有更多增長嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNBRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNBRA"/></p>
<p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和來自市場預測的金融數據生成的，以便為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 奧巴馬的民主黨全國委員會政變（來自 Stansberry Research）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjQ2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjQ2"/></p>
<h2>您現在是否應該投資$1,000 在 ACADIA Pharmaceuticals？</h2>
<p>在您考慮 ACADIA Pharmaceuticals 之前，您會想聽到這個。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户在更廣泛市場注意之前現在購買的股票... 而 ACADIA Pharmaceuticals 不在這個名單上。</p>
<p>儘管 ACADIA Pharmaceuticals 目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

阿卡迪亞

<p>阿卡迪亞製藥的目標股價由摩根大通從 30.00 美元下調至 28.00 美元，並給予該股票 “增持” 評級。其他幾份研究報告也已發佈關於阿卡迪亞製藥。公司股票目前有一個 “中等買入” 的共識評級，平均目標股價為 28.59 美元。阿卡迪亞製藥的股票交易價格為 17.74 美元，潛在上漲空間為 57.84%</p>

<p>ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) had its target price cut by investment analysts at Morgan Stanley from $30.00 to $28.00 in a report issued on Friday, Benzinga reports. The firm currently has an &#34;overweight&#34; rating on the biopharmaceutical company's stock. Morgan Stanley's price objective indicates a potential upside of 57.84% from the company's current price.</p>
<div class="lb-trans"><p>摩根士丹利的投資分析師在週五發佈的一份報告中將阿卡迪亞製藥（NASDAQ:ACAD）的目標股價從 30.00 美元下調至 28.00 美元。該公司目前對這家生物製藥公司的股票給予&#34;超配&#34;評級。摩根士丹利的價格目標表明，相較於公司當前股價，有 57.84% 的潛在上漲空間。</p>
</div><p>Get <strong>ACADIA Pharmaceuticals</strong> alerts:</p>
<ul>
<li>Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves</li>
</ul>
<div class="lb-trans"><p>獲取 <strong>阿卡迪亞製藥</strong> 的警報：</p>
<ul>
<li>阿卡迪亞製藥：中型生物科技公司正在發生重大變化</li>
</ul>
</div><p>ACAD has been the subject of several other research reports. Oppenheimer restated a &#34;market perform&#34; rating and issued a $19.00 price objective on shares of ACADIA Pharmaceuticals in a report on Monday, May 6th. Royal Bank of Canada reiterated an &#34;outperform&#34; rating and set a $29.00 price target on shares of ACADIA Pharmaceuticals in a report on Tuesday, June 25th. Robert W. Baird reduced their price target on ACADIA Pharmaceuticals from $31.00 to $28.00 and set an &#34;outperform&#34; rating for the company in a report on Thursday, May 9th. Mizuho reduced their price target on ACADIA Pharmaceuticals from $25.00 to $21.00 and set a &#34;neutral&#34; rating for the company in a report on Thursday, May 9th. Finally, JPMorgan Chase &amp; Co. reduced their price target on ACADIA Pharmaceuticals from $29.00 to $25.00 and set an &#34;overweight&#34; rating for the company in a report on Monday, March 25th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $28.59.</p>
<div class="lb-trans"><p>ACAD 已成為其他幾份研究報告的主題。Oppenheimer 重申了&#34;市場表現&#34;評級，並在 5 月 6 日的報告中對阿卡迪亞製藥的股票設定了 19.00 美元的價格目標。加拿大皇家銀行重申了&#34;表現優異&#34;評級，並在 6 月 25 日的報告中將阿卡迪亞製藥的股票目標價設定為 29.00 美元。Robert W. Baird 將阿卡迪亞製藥的目標股價從 31.00 美元下調至 28.00 美元，併為該公司設定了&#34;表現優異&#34;評級。Mizuho 將阿卡迪亞製藥的目標股價從 25.00 美元下調至 21.00 美元，併為該公司設定了&#34;中性&#34;評級。最後，摩根大通將阿卡迪亞製藥的目標股價從 29.00 美元下調至 25.00 美元，併為該公司設定了&#34;超配&#34;評級。四位股票研究分析師對該股票給予持有評級，十三位給予買入評級，一位給予強烈買入評級。根據 MarketBeat.com 的數據，該股目前的共識評級為&#34;中等買入&#34;，平均目標股價為 28.59 美元。</p>
</div><p><strong>View Our Latest Research Report on ACAD</strong></p>
<div class="lb-trans"><p><strong>查看我們對阿卡迪亞的最新研究報告</strong></p>
</div><h2>ACADIA Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>阿卡迪亞製藥股價表現</h2>
</div><p>Shares of ACAD traded up $0.09 during midday trading on Friday, hitting $17.74. The stock had a trading volume of 700,451 shares, compared to its average volume of 1,724,612. The firm has a market cap of $2.93 billion, a price-to-earnings ratio of -1,772.23 and a beta of 0.38. The company has a 50 day simple moving average of $15.58 and a two-hundred day simple moving average of $20.60. ACADIA Pharmaceuticals has a twelve month low of $14.55 and a twelve month high of $33.99.</p>
<div class="lb-trans"><p>週五午盤交易中，ACAD 股價上漲 0.09 美元，達到 17.74 美元。該股交易量為 700,451 股，相比平均交易量 1,724,612 股有所下降。該公司的市值為 29.3 億美元，市盈率為-1,772.23，β係數為 0.38。該公司的 50 天簡單移動平均線為 15.58 美元，200 天簡單移動平均線為 20.60 美元。阿卡迪亞製藥的 52 周最低價為 14.55 美元，最高價為 33.99 美元。</p>
</div><p>ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.06. The company had revenue of $205.83 million during the quarter, compared to analysts' expectations of $208.31 million. ACADIA Pharmaceuticals had a negative return on equity of 0.41% and a negative net margin of 0.21%. ACADIA Pharmaceuticals's revenue for the quarter was up 73.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.27) EPS. Analysts forecast that ACADIA Pharmaceuticals will post 0.58 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>阿卡迪亞製藥（NASDAQ:ACAD）於 5 月 8 日公佈了其季度財報。這家生物製藥公司報告稱，該季度每股收益為 0.10 美元，超過了每股 0.04 美元的共識預期 0.06 美元。該季度公司營收為 2.0583 億美元，低於分析師預期的 2.0831 億美元。阿卡迪亞製藥的淨資產回報率為-0.41%，淨利潤率為-0.21%。與去年同期相比，阿卡迪亞製藥的營收增長了 73.8%。去年同期，該公司每股收益為（0.27）美元。分析師預計，阿卡迪亞製藥本財年的每股收益將為 0.58 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部交易活動</h2>
</div><p>In other news, CEO Stephen Davis sold 11,427 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $16.94, for a total value of $193,573.38. Following the completion of the sale, the chief executive officer now directly owns 155,231 shares in the company, valued at $2,629,613.14. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other ACADIA Pharmaceuticals news, CFO Mark C. Schneyer sold 3,503 shares of the business's stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $16.94, for a total transaction of $59,340.82. Following the sale, the chief financial officer now owns 32,053 shares of the company's stock, valued at $542,977.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Stephen Davis sold 11,427 shares of the business's stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $16.94, for a total transaction of $193,573.38. Following the sale, the chief executive officer now directly owns 155,231 shares in the company, valued at approximately $2,629,613.14. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 20,708 shares of company stock worth $348,697. Corporate insiders own 28.30% of the company's stock.</p>
<div class="lb-trans"><p>另外，首席執行官 Stephen Davis 於 5 月 2 日星期四以每股 16.94 美元的均價出售了 11,427 股阿卡迪亞製藥股票。交易完成後，首席執行官在公司中直接持有 155,231 股股票，價值 2,629,613.14 美元。該交易已在提交給證券交易委員會的文件中披露，可通過此鏈接訪問。此外，首席財務官 Mark C. Schneyer 於 5 月 2 日星期四以每股 16.94 美元的均價出售了 3,503 股公司股票。交易總價值為 59,340.82 美元。交易完成後，首席財務官現在持有公司股票 32,053 股，價值 542,977.82 美元。該交易已在提交給證券交易委員會的法律文件中披露，可通過此鏈接訪問。此外，首席執行官 Stephen Davis 於 5 月 2 日星期四以每股 16.94 美元的均價出售了 11,427 股公司股票。交易總價值為 193,573.38 美元。交易完成後，首席執行官在公司中直接持有 155,231 股股票，價值約 2,629,613.14 美元。有關此次交易的披露可在此處找到。過去 90 天，內部人士共出售 20,708 股公司股票，價值 348,697 美元。公司內部人士持有公司股份的比例為 28.30%。</p>
</div><h2>Institutional Trading of ACADIA Pharmaceuticals</h2>
<div class="lb-trans"><h2>阿卡迪亞製藥的機構交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Empire Life Investments Inc. grew its stake in shares of ACADIA Pharmaceuticals by 0.3% during the fourth quarter. Empire Life Investments Inc. now owns 174,815 shares of the biopharmaceutical company's stock worth $5,473,000 after buying an additional 467 shares during the last quarter. Handelsbanken Fonder AB grew its stake in shares of ACADIA Pharmaceuticals by 2.3% in the fourth quarter. Handelsbanken Fonder AB now owns 31,633 shares of the biopharmaceutical company's stock worth $990,000 after purchasing an additional 700 shares during the last quarter. Swiss National Bank grew its stake in shares of ACADIA Pharmaceuticals by 0.4% in the first quarter. Swiss National Bank now owns 210,604 shares of the biopharmaceutical company's stock worth $3,894,000 after purchasing an additional 800 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of ACADIA Pharmaceuticals by 1.6% in the fourth quarter. Franklin Resources Inc. now owns 50,405 shares of the biopharmaceutical company's stock worth $1,578,000 after purchasing an additional 803 shares during the last quarter. Finally, Covestor Ltd grew its stake in shares of ACADIA Pharmaceuticals by 70.5% in the first quarter. Covestor Ltd now owns 2,032 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 840 shares during the last quarter. Institutional investors own 96.71% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近調整了他們對該股票的持股。Empire Life Investments Inc. 在第四季度增加了對 ACADIA Pharmaceuticals 股份的持股比例，增長了 0.3%。Empire Life Investments Inc. 現在擁有 174,815 股這家生物製藥公司的股票，價值$5,473,000，上季度購買了額外的 467 股。Handelsbanken Fonder AB 在第四季度增加了對 ACADIA Pharmaceuticals 股份的持股比例，增長了 2.3%。Handelsbanken Fonder AB 現在擁有 31,633 股這家生物製藥公司的股票，價值$990,000，上季度購買了額外的 700 股。瑞士國家銀行在第一季度增加了對 ACADIA Pharmaceuticals 股份的持股比例，增長了 0.4%。瑞士國家銀行現在擁有 210,604 股這家生物製藥公司的股票，價值$3,894,000，上季度購買了額外的 800 股。Franklin Resources Inc. 在第四季度增加了對 ACADIA Pharmaceuticals 股份的持股比例，增長了 1.6%。Franklin Resources Inc. 現在擁有 50,405 股這家生物製藥公司的股票，價值$1,578,000，上季度購買了額外的 803 股。最後，Covestor Ltd 在第一季度增加了對 ACADIA Pharmaceuticals 股份的持股比例，增長了 70.5%。Covestor Ltd 現在擁有 2,032 股這家生物製藥公司的股票，價值$38,000，上季度購買了額外的 840 股。機構投資者持有該公司股份的 96.71%。</p>
</div><h2>About ACADIA Pharmaceuticals (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 ACADIA Pharmaceuticals（獲取免費報告）</h2>
</div><p>ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.</p>
<div class="lb-trans"><p>ACADIA Pharmaceuticals Inc. 是一家生物製藥公司，專注於開發和商業化解決美國中樞神經系統（CNS）疾病和罕見疾病未滿足醫療需求的創新藥物。該公司提供 NUPLAZID（pimavanserin）用於治療帕金森病精神病的幻覺和妄想；以及 DAYBUE，一種胰島素樣生長因子 1 氨基末端三肽的新型合成類似物，用於治療雷特綜合徵。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than ACADIA Pharmaceuticals</li>
<li>The 3 Best Fintech Stocks to Buy Now</li>
<li>Top 3 Beverage Stocks: Summer Earnings Reveal Key Trends</li>
<li>Dividend King Proctor &amp; Gamble Is A Buy On Post-Earnings Weakness</li>
<li>This Financial Stock's Earnings Signal a Buying Opportunity</li>
<li>What Are Trending Stocks? Trending Stocks Explained</li>
<li>Social Platform Stock Hits New Highs: Is More Growth Ahead?</li>
</ul>
<div class="lb-trans"><h2>精選文章</h2>
<ul>
<li>五隻我們比 ACADIA Pharmaceuticals 更喜歡的股票</li>
<li>現在購買的 3 家最佳金融科技股</li>
<li>前三家飲料股：夏季收益揭示關鍵趨勢</li>
<li>股息王子寶潔在盈利下滑後值得購買</li>
<li>這家金融股的盈利信號表明購買機會</li>
<li>什麼是熱門股票？熱門股票解析</li>
<li>社交平台股價創新高：未來還有更多增長嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNBRA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ACAD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和來自市場預測的金融數據生成的，以便為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Obama’s DNC coup (From Stansberry Research)(Ad)</p>
<div class="lb-trans"><p>→ 奧巴馬的民主黨全國委員會政變（來自 Stansberry Research）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjQ2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8646&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in ACADIA Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資$1,000 在 ACADIA Pharmaceuticals？</h2>
</div><p>Before you consider ACADIA Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 ACADIA Pharmaceuticals 之前，您會想聽到這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户在更廣泛市場注意之前現在購買的股票... 而 ACADIA Pharmaceuticals 不在這個名單上。</p>
</div><p>While ACADIA Pharmaceuticals currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 ACADIA Pharmaceuticals 目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

阿卡迪亞製藥（NASDAQ:ACAD）的目標價被下調至 28.00 美元